SELLAS Life Sciences Group logo
SELLAS Life Sciences Group SLS
$ 4.86 7.65%

Annual report 2025
added 03-19-2026

report update icon

SELLAS Life Sciences Group Total Assets 2011-2026 | SLS

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.
Main categories of assets
Current assets (used within one year):
  • Cash and cash equivalents
  • Accounts receivable (amounts owed by customers)
  • Inventory of goods, raw materials, and supplies
  • Short-term investments
Non-current assets (used for more than one year):
  • Fixed assets (buildings, machinery, equipment)
  • Intangible assets (brands, patents, software)
  • Long-term investments
  • Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets SELLAS Life Sciences Group

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
78.3 M 19.4 M 6.22 M 20.9 M 26.3 M 46 M 16.6 M 16.9 M 33.5 M 65.8 M 82.1 M 80.5 M 88 M 55 M 31 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
88 M 6.22 M 44.4 M

Quarterly Total Assets SELLAS Life Sciences Group

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
51.6 M 32.3 M 35 M 19.4 M 26.5 M 15.1 M 24.4 M 6.22 M 8.09 M 18.6 M 29.1 M 20.9 M 26 M 32.2 M 21.4 M 26.3 M 38 M 43.6 M 40.6 M 46 M 46 M 46 M 46 M 16.6 M 16.6 M 16.6 M 16.6 M 16.9 M 16.9 M 16.9 M 16.9 M 33.5 M 33.5 M 33.5 M 33.5 M 6.42 M 65.8 M 65.8 M 65.8 M 82.1 M 82.1 M 82.1 M 82.1 M 80.5 M 80.5 M 80.5 M 80.5 M 88 M 88 M 88 M 88 M 55 M 55 M 55 M 55 M 31 M 31 M 31 M 31 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
88 M 6.22 M 42.7 M

Total Assets of other stocks in the Biotechnology industry

Issuer Total Assets Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
2.03 B - 2.43 % $ 254 M germanyGermany
Acorda Therapeutics Acorda Therapeutics
ACOR
109 M - -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
180 M - - $ 86.2 M usaUSA
AlloVir AlloVir
ALVR
122 M - 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
107 M - - $ 10.1 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
54.8 M - - $ 8.42 M usaUSA
I-Mab I-Mab
IMAB
6.33 B - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
18.1 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
151 M - 2.54 % $ 160 B franceFrance
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
433 M $ 24.58 5.63 % $ 3.13 B usaUSA
Biophytis SA Biophytis SA
BPTS
12 M - -13.47 % $ 169 M franceFrance
AVROBIO AVROBIO
AVRO
101 M - 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
7.77 M - - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
114 B - - $ 96.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
14.8 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
15.2 M - -1.52 % $ 24.7 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
8.19 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
41.4 M $ 3.85 2.41 % $ 9.26 B australiaAustralia
CymaBay Therapeutics CymaBay Therapeutics
CBAY
435 M - - $ 3.45 B usaUSA
Advaxis Advaxis
ADXS
16.6 M - -9.65 % $ 45.9 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
124 M $ 2.68 4.28 % $ 16.8 M usaUSA
Avid Bioservices Avid Bioservices
CDMO
337 M - - $ 789 M usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
215 M - - $ 1.41 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
1.51 B - - - russiaRussia
Cabaletta Bio Cabaletta Bio
CABA
165 M $ 3.08 0.33 % $ 309 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
7.47 M - - $ 169 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
35.1 M - 5.93 % $ 314 M canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
78.8 M - - $ 231 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
6.95 M - -10.17 % $ 12.2 K usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
165 M - - $ 401 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
778 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
66.7 M - - $ 26.5 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
126 M - - $ 1.2 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
113 M - 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
10 M - -45.71 % $ 1.2 M canadaCanada
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
8.18 M - -4.36 % $ 27 M usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
15 M $ 2.81 2.18 % $ 7.33 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
474 M - - $ 2.18 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
826 M - - $ 3.67 B usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
986 M - - $ 2.02 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
1.16 B - - $ 867 M germanyGermany
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
47.9 M $ 3.73 -1.84 % $ 251 B britainBritain
Akouos Akouos
AKUS
279 M - 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
244 M - - $ 28.6 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
34.8 M - 3.16 % $ 1.9 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
8.23 M - - $ 40.5 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
168 M $ 9.71 - $ 129 M usaUSA
Curis Curis
CRIS
20 M $ 0.55 0.05 % $ 7.24 M usaUSA
Epizyme Epizyme
EPZM
289 M - - $ 249 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
287 M - - $ 2.17 B usaUSA